Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suzanne F Jones

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignanciesHoward A Burris, Charles W Taylor, Suzanne F Jones, et al.
Oncology (Williston Park, N.Y.)|June 13, 2003
Phase I. Trial of irinotecan plus carboplatin in two dose schedulesSuzanne F Jones, Howard A Burris, John D Hainsworth, et al.
Clinical Lung Cancer|June 10, 2005
A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancerSuzanne F Jones, John G Kuhn, F Anthony Greco, et al.
Oncology (Williston Park, N.Y.)|June 13, 2003
Phase I. Trial of irinotecan and temozolomide in patients with solid tumorsSuzanne F Jones, Victor G Gian, F Anthony Greco, et al.
Cancer Chemotherapy and Pharmacology|August 27, 2013
A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumorsKyriakos P Papadopoulos, Howard A Burris, Michael Gordon, et al.
European Journal of Cancer (Oxford, England : 1990)|August 20, 2011
Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumoursPatrick Schöffski, Suzanne F Jones, Herlinde Dumez, et al.
Cancer Chemotherapy and Pharmacology|September 4, 2012
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumorsJeffrey R Infante, Vicki L Keedy, Suzanne F Jones, et al.
Investigational New Drugs|February 25, 2015
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumorsJohanna C Bendell, Carla Kurkjian, Jeffrey R Infante, et al.
JCO Precision Oncology|January 7, 2022
Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology ClinicsEmma G Sturgill, Amanda Misch, Rebecca Lachs, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2010
A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancerDavid R Spigel, John D Hainsworth, Jitendra G Gandhi, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignanciesHoward A Burris, Charles W Taylor, Suzanne F Jones, et al.
Oncology (Williston Park, N.Y.)|June 13, 2003
Phase I. Trial of irinotecan plus carboplatin in two dose schedulesSuzanne F Jones, Howard A Burris, John D Hainsworth, et al.
Clinical Lung Cancer|June 10, 2005
A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancerSuzanne F Jones, John G Kuhn, F Anthony Greco, et al.
Oncology (Williston Park, N.Y.)|June 13, 2003
Phase I. Trial of irinotecan and temozolomide in patients with solid tumorsSuzanne F Jones, Victor G Gian, F Anthony Greco, et al.
Cancer Chemotherapy and Pharmacology|August 27, 2013
A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumorsKyriakos P Papadopoulos, Howard A Burris, Michael Gordon, et al.
European Journal of Cancer (Oxford, England : 1990)|August 20, 2011
Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumoursPatrick Schöffski, Suzanne F Jones, Herlinde Dumez, et al.
Cancer Chemotherapy and Pharmacology|September 4, 2012
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumorsJeffrey R Infante, Vicki L Keedy, Suzanne F Jones, et al.
Investigational New Drugs|February 25, 2015
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumorsJohanna C Bendell, Carla Kurkjian, Jeffrey R Infante, et al.
JCO Precision Oncology|January 7, 2022
Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology ClinicsEmma G Sturgill, Amanda Misch, Rebecca Lachs, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2010
A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancerDavid R Spigel, John D Hainsworth, Jitendra G Gandhi, et al.
Pageof 7